The wellness platform’s results arrived amid heightened legal and regulatory scrutiny over its weight-loss-drug business.
Trending
- Stocks move to new session highs as buyers reclaim key technical levels
- ITV to cut show budgets as UK TV and film production spend drops by more than £2bn | ITV
- Credit Risk: Effect of Guarantor Support on Commercial Credit Risk Ratings
- OKXICE to Launch 24/7 Tokenized Stock Trading Despite Issuer Objections
- Rayonier is closing the valuation gap, but there’s more upside ahead
- Thai SEC Proposes New Standards for ICO Investor Tests
- Inflation Continues to Challenge U.S. Economy
- Corporate America is making a trillion-dollar mistake about retirement
Wednesday, November 11
